Swiss Medtechs Eye Near-Term Regulatory Progress On EU And FDA Fronts
Negotiators are juggling two big regulatory issues for Swiss medtechs and patients
An agreement between the EU and Switzerland potentially opening the way for renewal of the MRA – enabling barrier-free cross-border medtech trade – could be concluded as early as December. More good news for Switzerland, relating to the acceptance of FDA-approved products into the country, could follow in Q1 2025.
